Pharmaceutical giant Eli Lilly alleges the companies are selling illegal off-brand versions of its best-selling diabetes and ...

Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide ...

Compounded Ozempic and Wegovy, cheaper generic versions of the weight-loss drugs, can no longer be sold. Doctor explains ...

Spending on Ozempic, Wegovy and other similar prescriptions soared 500 percent in five years, according to a research letter.

Finding an inability of brand name GLP-1 manufacturers to keep up with patient demand for approved GLP-1 drugs, the FDA temporarily placed many of the approved GLP-1 drugs on the FDA shortage list ...

“Even though the GLP-1 drug classes have created hype ... A combination of phentermine and topiramate, which is sold under the brand name Qsymia, you can get for less than $20 a month.” ...

While you may be more familiar with brand names such as Ozempic or Wegovy, these drugs are known as glucagon-like peptide-1 (GLP-1) agonists in the medical world. Eli Lilly (NYSE: LLY) has emerged ...

10 Lori Chertoff, courtesy of the Rockefeller University Since its approval by the US Food and Drug Administration in 2021, semaglutide has been sold under the brand names Ozempic, Rybelsus, and ...

For decades, Americans have sought a “miracle drug” to combat obesity ... Glucagon-like peptide-1 receptor agonists, commonly known under brand names like Ozempic, first launched as diabetes ...

A type of drug that mimics the glucagon-like peptide-1 ... industry has begun responding to these shifts. For instance, some brands are introducing products aimed specifically at GLP-1 users. A ...

Potentially adding to a lengthening list of positive health benefits of GLP-1 agonist drugs, a new study has suggested they may also reduce the risk of a bevy of cancers associated with being very ...

Disruption is the New Name of the Game: Let’s face it ... to a combination of poor execution and fears of disruption by GLP-1 drugs. The business’ second-quarter 2024 results were surprisingly ...